Questionnaire

1. There are ethnic variations whereby South Asian, Chinese and black people have been found to develop diabetes at a higher rate, at an earlier age and at lower BMI ranges than their white counterparts.

2. A 5-15% weight reduction in people with T2DM has been demonstrated to improve CVD risk factors, including:

3. It has been demonstrated that remission of T2DM is maximal with weight loss of:

4. A weight loss of <5% has been associated with improved:

5. A weight loss of 5-10% has been associated with improved:

6. The DiRECT trial demonstrated that intensive weight management is a practical target within routine primary care for achieving remission of T2DM:

7. Glucose-lowering therapies with very high dual glucose and weight efficacy that are recommended by the ADA/EASD for achievement and maintenance of weight management goals are:

8. Data from the SUSTAIN studies of semaglutide demonstrated that, compared with the comparator in all trials, there was a significant and sustained HbA_1c reduction of:

9. Data from the SUSTAIN studies of semaglutide demonstrated significant weight reductions of approximately:

10. Data from the SUSTAIN studies of semaglutide vs a comparator demonstrated that semaglutide doses of 0.5mg and 1.0mg were associated with a significantly greater percentage of participants achieving weight loss of:

11. The percentage of participants with T2DM who achieved ≥15% weight loss in the STEP programme evaluating semaglutide 2.4mg once-weekly was approximately:

12. Compared with participants who received placebo in the STEP programme, those who received semaglutide 2.4mg once-weekly experienced a greater improvement in:

13. Tirzepatide is a once-weekly dual GLP-1/SGLT2 RA.

14. The SURPASS clinical trials of tirzepatide 5mg, 10mg and 15mg across the spectrum of T2DM have demonstrated:

15. Meta-analysis of clinical trials investigating the effect of SGLT2is on body composition in patients with T2DM demonstrate improvements in: